Cytokines: General information, pharmacokinetics, indications, and limitations of its clinical use for cancer treatment
Guardado en:
| Autores: | , , , , , , |
|---|---|
| Fecha de Publicación: | 2023 |
| Descripción: | Cancer is a genetic disease that ranks among the leading causes of death worldwide. It accounted for about 10 million deaths in 2020, representing one in six global fatalities. Although therapies such as surgery, chemotherapy, and radiotherapy are available, the survival rate of patients is low. Therefore, research to find new therapeutic strategies is a priority. As a result of these studies, immunotherapy was developed, through which it is sought that a person's immune system can fight cancer cells by administering substances such as cytokines. When secreted by the organism, these proteins function as mediators between effector cells, thereby regulating the inflammatory and immune response and acting as growth factors for cells such as hematopoietic ones. Despite its therapeutic potential, their high toxicity and complex pharmacokinetics have limited their consideration since only anti-cancer indications have been approved for IL-2 and IFN-α. Even with this, research by the pharmaceutical industry continues to assess safe and effective novel therapies against cancer and other pathologies involving these molecules. |
| País: | Kérwá |
| Institución: | Universidad de Costa Rica |
| Repositorio: | Kérwá |
| Lenguaje: | Inglés |
| OAI Identifier: | oai:kerwa.ucr.ac.cr:10669/105086 |
| Acceso en línea: | http://www.ijptb.com/archive.php?year=2023&&vol=10 https://hdl.handle.net/10669/105086 |
| Palabra clave: | Biotechnology Immune system Cytokine Cancer Immunotherapy Medical treatment Pharmacology Medical research Immunology |